MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Clinical trials for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major trial aims to halt progression of scarred livers
Disease control Recruiting nowThis large, late-stage study is testing whether a drug called efruxifermin can slow down or reverse liver damage in people who already have significant scarring (cirrhosis) from fatty liver disease (NASH/MASH). About 1,150 participants will receive either the drug or a placebo to…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug trial aims to control serious fatty liver disease
Disease control Recruiting nowThis study is testing the safety and effectiveness of a drug called Resmiterom for people with MASH, a serious type of fatty liver disease that can lead to scarring. It will involve 165 patients in Pakistan who have been diagnosed with MASH and at least one related health conditi…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE4 • Sponsor: Nabiqasim Industries (Pvt) Ltd • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Old heart drug could be new hope for millions with fatty liver
Disease control Recruiting nowThis study is testing if digoxin, a medication used for heart conditions, can help treat a serious liver disease called NASH (now called MASH). Researchers will give 144 people with NASH either digoxin or a placebo pill daily for 24 weeks to see if it reduces liver inflammation a…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug trial targets dangerous liver fat
Disease control Recruiting nowThis study is testing an investigational drug called HU6 to see if it is safe and can reduce harmful fat in the liver for people with MASH, a serious form of fatty liver disease. About 180 adults aged 30 and older with MASH will receive either HU6 or a placebo for 26 weeks, and r…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Rivus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Early trial tests new shot for common liver disease
Disease control Recruiting nowThis early-stage study aims to find out if a new injectable medicine called TGM-312-SC01 is safe and how it behaves in the body. It will first test single doses in healthy adults, then test multiple doses in adults diagnosed with MASH, a serious form of fatty liver disease. The m…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE1, PHASE2 • Sponsor: Tangram Therapeutics Plc • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Scientists search for hidden clues linking liver and colon health
Knowledge-focused Recruiting nowThis study aims to understand how fatty liver disease (MASH) might be connected to the development of colon polyps. Researchers will analyze tissue and blood samples from 100 people already scheduled to have polyps removed during a routine colonoscopy. The goal is to find molecul…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Sponsor: Shanghai East Hospital • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:09 UTC